Bliss GVS Pharma adopts two ESOP policies, grants 73.5 Lac options

Bliss GVS Pharma Ltd's Board of Directors, at its meeting on October 01, 2026, approved the adoption of two new Employee Stock Option Policies (ESOPs): the Senior Executive Employee Stock Option Policy 2026 and the Employee Stock Option Policy 2026. These policies, subject to shareholder and regulatory approvals, facilitate the grant of stock options to employees. Under the Senior Executive ESOP 2026, up to 26,50,000 equity shares (approximately 2.49% of fully diluted paid-up capital) can be granted at a discounted fixed exercise price of ₹10 per share, with a minimum one-year vesting period. The Employee ESOP 2026 allows for the grant of up to 47,00,000 equity shares. The total options granted under both policies amount to 73,50,000 equity shares.